A guide for stabilization of pharmaceuticals to oxidation is presented. Literature is presented with an attempt to be a ready source for data and recommendations for formulators. Liquid and solid dosage forms are discussed with options including formulation changes, additives, and packaging documented. In particular, selection of and methods for use of antioxidants are discussed including recommended levels.
In physiological compartments, provided with suitable reducing agents, transition metals are able to catalyze the activation of O 2 to various reactive oxygen species (ROS) 1 which readily attack biomolecules. The metal-catalyzed oxidation (MCO) of proteins plays an important role during oxidative stress and aging where modified proteins may accumulate in tissue (1-9). In addition, MCO also presents a stability problem for the biotechnological manufacturing of proteins (10, 11).A unique feature often observed during MCO of proteins is that only a few amino acid residues within a certain domain of the given protein are modified (2, 12). Such site specificity is attributed to the generation of ROS at specific metal-binding sites, where the highly reactive ROS attack labile functional groups nearby rather than diffuse into the bulk medium. It has been shown that most of the enzymes labile to MCO require metals for activity (13). The oxidation of these enzymes is less sensitive to the inhibition by exogenous ROS scavengers than would be expected on the basis of known rate constants for the reactions of specific ROS with these scavengers. However, one problem associated with all these studies is that neither the oxidizing species nor the intermediary protein-transition metal complexes formed during MCO of proteins have been well characterized. This is most pertinent to copper-catalyzed oxidation (i.e. to the frequently used ascorbate/Cu(II)/O 2 system) involving the Cu(II)/Cu(I) redox couple (2). Here, Cu(II) will most probably require a different geometry and different ligands within the protein ligand sphere than Cu(I). An initial reduction of Cu(II), bound to a metal-binding site, to Cu(I) may change the geometry of the protein-metal complex, and possibly even release Cu(I) from the metal-binding site. On the other hand, the metal may be retained when (i) the protein is flexible enough to adapt to the new geometrical requirements of the reduced metal, or (ii) re-oxidation of the metal by molecular oxygen or reduction products of molecular oxygen such as superoxide or hydrogen peroxide occurs faster than the release of the reduced metal from the metal-binding site.In a recent example for electron transfer coupled ligand dynamics in the model complex Cu(I/II)(TTCN) 2 , we could show that oxidation of tetrahedral [Cu(I)(TTCN) 2 ] ϩ potentially led to the loss of a ligand to yield [Cu(II)(TTCN)(H 2 O) 3 ] 2ϩ before geometrical reorganization around the Cu(II) atom allowed the addition of TTCN to give the final product, octahedral [Cu(II)(TTCN) 2 ] 2ϩ . 2 Analogous mechanisms may lead to kinetic complexities during protein oxidation which may be reflected in oxidation yields and kinetics as well as the nature of the oxidation products.One amino acid particularly affected by MCO is histidine (His) (15-17). There is as yet no detailed mechanism available for His oxidation in proteins, except a crystallographic study which showed the feasibility of metal-catalyzed processes within the metal-binding domain of glutamine syn...
This literature review presents hydrolysis of active pharmaceutical ingredients as well as the effects on dosage form stability due to hydrolysis of excipients. Mechanisms and measurement methods are discussed and recommendations for formulation stabilization are listed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.